![]() ![]() ![]() Interrupt and/or dose reduce for decreased LVEF. Discontinue sunitinib malate capsules for clinical manifestations of congestive heart failure. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Cardiovascular Events: Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. ![]() Discontinue sunitinib malate capsules in patients with Grade 4 hepatotoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. Interrupt sunitinib malate capsules for Grade 3 hepatotoxicity until resolution to Grade ≤ 1 or baseline and resume sunitinib malate capsules at a reduced dose discontinue if no resolution. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Hepatotoxicity: Fatal liver failure has been observed. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |